| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 12 nM (Citron kinase, CITK)[1]
C3TD879 is a selective, first-in-class Type I inhibitor targeting citron kinase (CITK), an AGC family serine/threonine kinase essential for the final stage of cell division, cytokinesis. C3TD879 binds directly to human CITK (NanoBRET Kd < 10 nM) and inhibits its catalytic activity with an IC50 of 12 nM. By inhibiting CITK, the compound disrupts cytokinesis, leading to the formation of multinucleated cells and ultimately cell death. This mechanism offers a potential therapeutic strategy for cancers that are reliant on CITK function. |
|---|---|
| ln Vitro |
In vitro, C3TD879 is a potent Type I kinase inhibitor that selectively targets CITK with an IC50 of 12 nM. It binds directly to full-length human CITK in cells (NanoBRET Kd < 10 nM). At concentrations that inhibit CITK catalytic activity, C3TD879 does not induce cell proliferation, cell cycle progression, or cytokinesis defects similar to those observed with CITK knockdown. This suggests that the compound may have a unique mechanism of action or that it affects other pathways. Detailed cellular IC50 values for specific cancer cell lines were not provided in the search results.
|
| ln Vivo |
Detailed in vivo data for C3TD879 was not available in the search results. However, as a first-in-class, selective CITK inhibitor, the compound has the potential for in vivo efficacy in cancers where CITK is overexpressed or plays a critical role. CITK is known to be upregulated in various tumor types. Its role in cytokinesis makes it a target for cancer therapy. In vivo studies would likely involve xenograft models of cancers such as ovarian, breast, or colorectal cancer. Future research will focus on evaluating its antitumor activity in these models.
|
| Enzyme Assay |
The in vitro CITK kinase inhibition assay is performed using a radiometric or fluorescence-based method. Purified recombinant human CITK enzyme (1-10 nM) is incubated in a kinase buffer containing 10 uM ATP (including 0.5 uCi of [gamma-32P]-ATP for radiometric assays) and a specific peptide substrate (e.g., a generic peptide or a specific CITK substrate). Varying concentrations of C3TD879 (0-1000 nM) are added. The reaction is incubated at 30degC for 30-60 minutes and then stopped. The phosphorylated substrate is separated and quantified, and the IC50 (12 nM) is calculated. The cellular target engagement is measured using a NanoBRET assay, where the binding Kd is determined.
|
| Cell Assay |
For cell-based assays, cancer cells expressing endogenous CITK are used to assess the effect of CITK inhibition on cell proliferation, cytokinesis, and the cell cycle. Cells are seeded in 6-well plates (3×10⁵ cells/well) and treated with varying concentrations of C3TD879 (1-1000 nM) for 24-72 hours. Cell proliferation is measured by counting cells or using an MTT assay. To assess cytokinesis defects, cells are fixed and stained with DAPI and an antibody against a cytoskeletal marker (e.g., alpha-tubulin). The percentage of cells with multinucleated or binucleated morphology is quantified by fluorescence microscopy. The IC50 for the induction of multinucleation is determined.
|
| Animal Protocol |
A standard in vivo protocol for evaluating a CITK inhibitor would involve a xenograft model using a cancer cell line with high CITK expression. Female BALB/c nude mice (6-8 weeks old) would be subcutaneously injected with 5×10⁶ cancer cells (e.g., HeLa cervical cancer or other CITK-dependent cells). Once tumors reach a volume of approximately 100-150 mm3, mice would be randomized into groups (n=8-10) and treated with C3TD879. The compound would be formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween 80, 45% saline) and administered by intraperitoneal (IP) injection at doses of 10-50 mg/kg. Tumor volume would be measured every 2-3 days for 2-3 weeks.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for C3TD879 was not available in the search results. As a small molecule (MW 364.5), it is expected to be cell-permeable. The compound is predicted to have moderate to good oral bioavailability, but no specific parameters (Cmax, Tmax, t½, oral bioavailability) were reported. For in vivo studies, the compound can be formulated in 10% DMSO, 40% PEG300, 5% Tween 80, and 45% saline for intraperitoneal administration. Further PK studies would be required to assess its absorption and distribution characteristics.
|
| Toxicity/Toxicokinetics |
No specific toxicological data for C3TD879 was available in the search results. As a first-in-class inhibitor, its safety profile has not yet been extensively characterized. However, the compound's selectivity for CITK and its unique cellular effects suggest it may have a different safety margin compared to broader-spectrum kinase inhibitors. As a research chemical, standard safety precautions should be followed when handling. This includes wearing appropriate personal protective equipment (PPE) such as gloves, lab coats, and safety goggles. Work should be conducted in a well-ventilated area, such as a chemical fume hood.
|
| References | |
| Additional Infomation |
C3TD879 is a research-grade, first-in-class, selective inhibitor of citron kinase (CITK). It serves as a valuable chemical probe for investigating the biological function of CITK in cytokinesis, cell cycle progression, and tumorigenesis. This compound is also being evaluated as a potential lead for the development of novel cancer therapies targeting CITK. It is not an FDA-approved drug and is for research use only.
|
| Molecular Formula |
C22H28N4O
|
|---|---|
| Molecular Weight |
364.48
|
| CAS # |
2850259-33-3
|
| Appearance |
White to off-white solid powder
|
| Density |
1.165±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
|
| LogP |
0
|
| SMILES |
O=C([C@@H](CC(C)(C)C)N)NC1C=CC(=C(C)C=1)C1C=CN=C2C=1C=C(C)N2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~274.36 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.86 mM)(saturation unknown) in 10% DMSO 40% PEG300 5% Tween-80 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300, mix well; then add 50 μL Tween-80 to the above system, mix well; then continue to add 450 μL of normal saline to make up to 1 mL. Preparation of normal saline: Dissolve 0.9 g of sodium chloride in ddH₂O and make up to 100 mL to obtain a clear and transparent normal saline solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.86 mM)(saturation unknown) in 10% DMSO 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. 2 g SBE-β-CD (sulfobutyl ether β-cyclodextrin) powder is diluted to 10 mL of saline and completely dissolved until clear and transparent. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.86 mM)(saturation unknown) in 10% DMSO 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7436 mL | 13.7182 mL | 27.4363 mL | |
| 5 mM | 0.5487 mL | 2.7436 mL | 5.4873 mL | |
| 10 mM | 0.2744 mL | 1.3718 mL | 2.7436 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
